You have the right to live your life to the fullest — today and tomorrow.
Read more
Interim report January-September 2025
Our businesses continued to perform well in Q3.
Read the report
Stock exchange releases
- 1/16/2026 182,827 Orion Corporation A shares converted into B shares
- 1/15/2026 Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
- 1/14/2026 Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
- 1/14/2026 Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
Press releases
- 1/8/2026 Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
- 11/14/2025 Orion receives award for international growth from the President of the Republic of Finland
- 10/23/2025 Orion and Abzena announce exclusive commercial license for Abzena’s antibody
- 10/14/2025 Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025